Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.37 |
| ▸ | CDK2 | P24941 | 11/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 10/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.37 |
| ▸ | CDK1 | P06493 | 5/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.37 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | CCND1 | P24385 | 4/20 | 0.37 |
| ▸ | CCND3 | P30281 | 2/20 | 0.37 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179490 | 0.82 | CCNE1 (0.52) | CNR2CCNE1CDK2CCNE2CCNB2 | |
| SCHEMBL10183729 | 0.75 | LMNA (0.42) | CNR2CCNE1CDK2CCNE2CCNB2 | |
| SCHEMBL20877512 | 0.73 | CA1 (0.47) | CNR2CCNE1CDK2CCNE2CCNB2 | |
| SCHEMBL12851970 | 0.73 | RAB9A (0.62) | CNR2CCNE1CDK2CCNE2CCNB2 | |
| SCHEMBL19261385 | 0.73 | CCND3 (0.43) | CNR2CCNE1CDK2CCNE2CCNB2 | |
| SCHEMBL14012575 | 0.73 | CNR2 (0.36) | CNR2FFAR2PSEN1PSEN2APH1B | |
| SCHEMBL18469870 | 0.73 | CNR2 (0.36) | CNR2CCND3FFAR2PSEN1PSEN2 | |
| SCHEMBL17244883 | 0.71 | CDK2 (0.63) | CCNE1CDK2CCNE2CCNB2CDK1 | |
| SCHEMBL11915994 | 0.71 | KDR (0.62) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL12754630 | 0.70 | LIMK1 (0.37) | CNR2CCNE1CDK2CCNE2FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885CCNE1 1333/4885CDK2 100/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885CCNE1 1333/4885CDK2 100/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885CCNE1 1333/4885CDK2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.